Apogee Therapeutics (APGE) Competitors

$135.07 0.00 (0.00%)

As of 09/4/2026

APGE vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy Apogee Therapeutics stock or one of its competitors? Apogee Therapeutics's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Apogee Therapeutics (NASDAQ:APGE) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Alnylam Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Alnylam Pharmaceuticals	$3.71B	8.63	$313.75M	$5.38	44.53

Apogee Therapeutics presently has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Alnylam Pharmaceuticals has a consensus target price of $367.20, suggesting a potential upside of 53.28%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Apogee Therapeutics. MarketBeat recorded 10 mentions for Alnylam Pharmaceuticals and 0 mentions for Apogee Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 0.14 beat Apogee Therapeutics' score of 0.00 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Alnylam Pharmaceuticals	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Apogee Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apogee Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Apogee Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biogen presently has a consensus target price of $230.14, suggesting a potential upside of 6.79%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Biogen had 20 more articles in the media than Apogee Therapeutics. MarketBeat recorded 20 mentions for Biogen and 0 mentions for Apogee Therapeutics. Biogen's average media sentiment score of 0.90 beat Apogee Therapeutics' score of 0.00 indicating that Biogen is being referred to more favorably in the media.

Company	Overall Sentiment
Biogen	Positive
Apogee Therapeutics	Neutral

Biogen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.22	$1.29B	$5.65	38.14
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Biogen has a net margin of 8.32% compared to Apogee Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Summary

Biogen beats Apogee Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Roivant Sciences had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 0 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 0.91 beat Apogee Therapeutics' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Roivant Sciences	Positive
Apogee Therapeutics	Neutral

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Roivant Sciences presently has a consensus price target of $45.64, suggesting a potential upside of 14.75%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

Apogee Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Apogee Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Roivant Sciences beats Apogee Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Insmed?

Apogee Therapeutics (NASDAQ:APGE) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Insmed had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 5 mentions for Insmed and 0 mentions for Apogee Therapeutics. Insmed's average media sentiment score of 0.86 beat Apogee Therapeutics' score of 0.00 indicating that Insmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Insmed	Positive

Apogee Therapeutics presently has a consensus price target of $126.77, indicating a potential downside of 6.14%. Insmed has a consensus price target of $204.91, indicating a potential upside of 70.76%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Apogee Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Apogee Therapeutics has higher earnings, but lower revenue than Insmed. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Insmed	$606.42M	43.21	-$1.28B	-$4.11	N/A

Apogee Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Apogee Therapeutics' return on equity of -29.88% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Insmed beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Incyte has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.94	$1.29B	$7.85	15.96
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Incyte has a net margin of 27.71% compared to Apogee Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Incyte presently has a consensus target price of $124.05, suggesting a potential downside of 1.01%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Given Incyte's stronger consensus rating and higher probable upside, research analysts plainly believe Incyte is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

97.0% of Incyte shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Incyte had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Incyte and 0 mentions for Apogee Therapeutics. Incyte's average media sentiment score of 0.62 beat Apogee Therapeutics' score of 0.00 indicating that Incyte is being referred to more favorably in the media.

Company	Overall Sentiment
Incyte	Positive
Apogee Therapeutics	Neutral

Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Summary

Incyte beats Apogee Therapeutics on 14 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.40B	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-31.12	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	7.03	15.45	10.46	6.33
Net Income	-$255.84M	-$22.86M	$3.49B	$358.33M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	0.24%	-3.29%	-1.74%	-2.39%
1 Year Performance	269.75%	37.74%	18.13%	5.35%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	1.048 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91
ALNY Alnylam Pharmaceuticals	4.3313 of 5 stars	$242.64 -2.9%	$376.67 +55.2%	-47.2%	$32.41B	$3.71B	45.02	2,770
BIIB Biogen	3.4834 of 5 stars	$215.96 -0.6%	$230.14 +6.6%	+51.2%	$31.90B	$9.89B	38.21	7,500	Positive News
ROIV Roivant Sciences	2.8169 of 5 stars	$39.58 -3.5%	$40.63 +2.6%	+164.4%	$28.61B	$7.53M	N/A	721	Analyst Forecast Insider Trade
INSM Insmed	3.0433 of 5 stars	$119.89 -4.3%	$205.52 +71.4%	-17.1%	$26.16B	$1.14B	N/A	1,664	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Apogee Therapeutics compare to Biogen?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Summary

How does Apogee Therapeutics compare to Insmed?

Summary

How does Apogee Therapeutics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Which has higher earnings and valuation, APGE or ALNY?

Do analysts prefer APGE or ALNY?

Does the media prefer APGE or ALNY?

Is APGE or ALNY more profitable?

Do institutionals & insiders have more ownership in APGE or ALNY?

Which has more risk & volatility, APGE or ALNY?

Summary

How does Apogee Therapeutics compare to Biogen?

Which has more risk & volatility, BIIB or APGE?

Do institutionals and insiders hold more shares of BIIB or APGE?

Do analysts rate BIIB or APGE?

Does the media refer more to BIIB or APGE?

Which has stronger valuation & earnings, BIIB or APGE?

Is BIIB or APGE more profitable?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Does the media refer more to ROIV or APGE?

Do insiders and institutionals have more ownership in ROIV or APGE?

Which has more risk & volatility, ROIV or APGE?

Do analysts prefer ROIV or APGE?

Is ROIV or APGE more profitable?

Which has stronger valuation & earnings, ROIV or APGE?

Summary

How does Apogee Therapeutics compare to Insmed?

Do institutionals and insiders believe in APGE or INSM?

Does the media prefer APGE or INSM?

Do analysts recommend APGE or INSM?

Which has more volatility & risk, APGE or INSM?

Which has preferable valuation & earnings, APGE or INSM?

Is APGE or INSM more profitable?

Summary

How does Apogee Therapeutics compare to Incyte?

Which has higher earnings and valuation, INCY or APGE?

Is INCY or APGE more profitable?

Do analysts recommend INCY or APGE?

Do institutionals and insiders hold more shares of INCY or APGE?

Does the media favor INCY or APGE?

Which has more risk & volatility, INCY or APGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools